prIME Conference on Colorectal Cancer: Current and Emerging Strategies in Multidisciplinary Management will update you with the latest advances in the management of colorectal cancer (CRC) and will provide you with guidance on how to best implement new evidence into clinical practice to improve patient outcomes and quality of life. In addition to extensive evaluation of clinical and molecular biomarkers and systemic treatment options, this conference also offers a practical perspective on how to optimize multidisciplinary care that requires complex clinical treatment decisions and integrate locoregional treatment modalities into different clinical situations.
Date and Location
Saturday, 20 April 2019
08.00 – 17.20
Room: Infinity Ballroom
1 Dong Fang Rd
North Dongsanhuan Rd
Saturday, 20 April 2019
|08.00||Registration and welcome coffee|
|08.30||Introduction and demographics
Dirk Arnold, MD, PhD; Ruihua Xu, MD, PhD; and prIME Oncology Medical Director
|08.40||Quiz: Are you up to date with advances in CRC management?|
|08.50||Accomplishments and challenges in the management of CRC in Asia
Yuan Ying, MD, PhD
|09.15||Q & A|
|09.25||Keynote presentation—Precision therapy for CRC in the era of next-generation sequencing
Julien Taïeb, MD, PhD
|09.50||Q & A|
|10.20||Latest recommendations for multidisciplinary management of CRC liver metastases
Eiji Oki, MD, PhD, FACS
|10.50||Commentary: Is cure possible in patients with unresectable colorectal liver metastases?
Jianmin Xu, MD, PhD
|11.05||Q & A|
|11.15||Clinical cases of CRC with oligometastatic metastases: Challenging questions for the multidisciplinary team
Moderator: Jianmin Xu, MD, PhD
|13.15||Planning treatment for RAS-wildtype mCRC: First-line and across disease continuum
Tianshu Liu, MD, PhD
|13.40||Q & A|
|13.50||Managing BRAF-mutant mCRC in 2019: Maximizing targeted approaches
Dirk Arnold, MD, PhD
|14.10||Q & A|
|14.20||Clinical cases of mCRC: Challenging questions for the multidisciplinary team
Moderator: Ruihua Xu, MD, PhD
|15.20||Liquid biopsy in CRC: Clinical applications
Ruihua Xu, MD, PhD
|15.40||Q & A|
|15.50||Updates on immunotherapy in mCRC: Current status and ongoing efforts
Li-Tzong Chen, MD, PhD
|16.10||Q & A|
|16.15||Total neoadjuvant therapy: A novel strategy for locally advanced rectal cancer
Hiroya Taniguchi, MD, PhD
|16.35||Q & A|
|16.40||Clinical case of rectal cancer: Challenging questions for the multidisciplinary team
Moderator: Dirk Arnold, MD, PhD
|17.00||Quiz questions revisited and faculty commentary|
Dirk Arnold, MD, PhD, and Ruihua Xu, MD, PhD
Dirk Arnold, MD, PhDAsklepios Clinic Altona
Ruihua Xu, MD, PhDSun Yat-sen University Cancer Center
Li-Tzong Chen, MD, PhDNational Institute of Cancer Research
National Health Research Institutes
Tianshu Liu, MD, PhDZhongshan Hospital
Eiji Oki, MD, PhD, FACSKyushu University
Julien Taïeb, MD, PhD Georges Pompidou European Hospital
Hiroya Taniguchi, MD, PhDNational Cancer Center Hospital East
Jianmin Xu, MD, PhDZhongshan Hospital
Yuan Ying, MD, PhDThe Second Affiliated Hospital
Zhejiang University School of Medicine
This educational activity is specifically designed for medical oncologists, gastroenterologists, surgical and radiation oncologists, and other healthcare professionals involved in the management of CRC in the Asia Pacific (APAC) region.
After successful completion of this educational activity, participants should be able to:
- Evaluate current and emerging biomarkers to guide precision medicine in metastatic CRC (mCRC) and the potential role of liquid biopsy in the management of early and metastatic CRC
- Select multidisciplinary treatment approaches that may lead to optimal treatment outcomes for patients with oligometastatic disease (eg, liver-only metastases)
- Determine the best front-line therapy for mCRC based on patient and tumor characterisitcs and assess treatment beyond disease progression
- Identify therapeutic options for BRAF-mutant mCRC
- Explain treatment options for locally advanced rectal cancer
- Describe emerging agents and treatment strategies in mCRC including the role of immunotherapy in mCRC and anti-EGFR rechallenge
This educational activity is supported by a grant from Merck KGaA, Darmstadt, Germany.
An application has been made to the EACCME® for CME Accreditation of this event.
This activity is provided by prIME Oncology.
prIME Oncology complies with all Sunshine Act reporting requirements as outlined by CMS and applicable manufacturers and with EFPIA Disclosure Code reporting requirements.
Americans With Disabilities Act
Event staff will be glad to assist you with any special needs (physical, dietary, etc).
Disclosure of Relevant Financial Relationships
prIME Oncology assesses the relevant financial relationships of its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.
Disclosure Regarding Unlabeled Use
This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.